Company: RGNX
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001193125-25-053998
Chunk: 11

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 11
---
 with each holder, the number of pre-fundedwarrants that may be exercised at any given time may be limited if, upon exercise, the warrant holder and any of its affiliates would beneficially own more than 9.99% of our common stock, or have voting power of more than 9.99% of our common stock. The limitation may be increased or decreased by the warrant holder, with advance notice to us, to any other percentage not less than 4.99% nor in excess of 19.99%. Pre-fundedwarrants do not provide any of the rights or privileges provided by our common stock, including any voting rights, until the pre-fundedwarrants are exercised and settled in underlying shares of common stock. Preferred Stock General We may issue shares of preferred stock from time to time in one or more series, the terms of which may be determined at the time of issuance by our board of directors, without further action by our stockholders. Such series of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. The shares of each series of preferred stock will have preferences, limitations and relative rights, including voting rights, identical with those of other shares of the same series and, except to the extent provided in the description of such series, of those of other series of preferred stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of common stock or adversely affect the rights and powers, including voting rights, of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company, which could depress the market price of our common stock. The terms of any particular series of preferred stock will be described in the prospectus supplement relating to the offering of shares of such series of preferred stock, including, where applicable:

| • |     | the series designation, stated value and liquidation preference of such preferred stock; |

| • |     | the number of shares offered; |

| • |     | the offering price; |

| • |     | the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and                            
 whether such dividends shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate; |

| • |     | any redemption